Disruption of cholesterol efflux by coxib medications and inflammatory processes: Link to increased cardiovascular risk

Journal of Investigative Medicine

Volumn 57, Issue 6, 2009, Pages 695-702

  Reiss, Allison B ^a   Anwar, Farah ^a   Chan, Edwin S L ^b   Anwar, Kamran ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

27 hydroxylase; ABCA1; Atherosclerosis; Cyclooxygenase inhibitor; Foam cell

Indexed keywords

ABC TRANSPORTER A1; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CYCLOOXYGENASE 2 INHIBITOR; METHOTREXATE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE;

ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL OUTFLOW; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; DRUG EFFECT; EFFUSION; ENZYME STRUCTURE; FOAM CELL; INFLAMMATION; LIPID STORAGE; MACROPHAGE; MONOCYTE; PROTEIN EXPRESSION; REGULATORY MECHANISM; RISK REDUCTION; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CHOLESTEROL; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CYCLOOXYGENASE 2 INHIBITORS; HUMANS;

EID: 70349310097     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e31819ec3c7     Document Type: Conference Paper

References (80)

1. Vonkeman HE, Klok RM, Postma MJ, et al. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs Aging. 2007;24: 681-690.
2. Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 2005;100: 1685-1693.
3. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br Med J. 2005;330: 1366-1373.
4. Fosbøl E, Gislason G, Jacobsen S, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85: 190-197.
5. Dogne JM, Hanson J, Supuran C, et al. Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des. 2006;12: 971-975.
6. Bannwarth B. Acetaminophen or NSAIDs for the treatment of osteoarthritis. Best Pract Res Clin Rheumatol. 2006;20: 117-129.
7. Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59: 1097-1104.
8. Chan FK, Abraham NS, Scheiman JM, et al. First InternationalWorking Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-Platelet Agents. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Antiinflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol. 2008;103: 2908-2918.
9. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109: 2068-2073.
10. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006;296: 1653-1656.
11. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A. 1999;96: 272-277.
12. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ. 2002;167: 1131-1137.
13. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population based cohort study. Lancet. 2004;363: 1751-1756.
14. Aw T-J, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165: 490-496.
15. Frishman WH. Effects of non-steroidal anti-inflammation drug therapy on blood pressure and peripheral edema. Am J Cardiol. 2002;89: 18D-25D.
16. Rodriguez F, Llinas MT, Gonzalez JD, et al. Renal changes induced by a cyclooxygenase-2 inhibitor during normal and low sodium intake. Hypertension. 2000;36: 276-281.
17. Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther. 1999;66: 76-84.
18. Jensen BL, Schmid C, Kurtz A. Prostaglandins stimulate renin secretion and renin mRNA in mouse renal juxtaglomerular cells. Am J Physiol Renal Fluid Electrolyte Physiol. 1996;271: F659-F669.
19. Stichtenoth DO, Wagner B, Frolich JC. Effect of selective inhibition of the inducible cyclooxygenase on renin release in healthy volunteers. J Investig Med. 1998;46: 290-296.
20. Harris RC, Breyer MD. Update on cyclo-oxygenase-2 inhibitors. Clin J Am Soc Nephrol. 2006;1: 236-245.
21. Cheng HF, Wang JL, Zhang MZ, et al. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol. 2001;280: F449-F456.
22. Francois H, Coffman TM. Prostanoids and blood pressure: which way is up? J Clin Invest. 2004;114: 757-759.
23. Nasrallah R, Clark J, Hébert RL. Prostaglandins in the kidney: developments since Y2K. Clin Sci (Lond). 2007;113: 297-311.
24. Vinereanu D. Risk factors for atherosclerotic disease: present and future. Herz. 2006;(suppl 3): 5-24.
25. Hobbs R, Hoes A. Effective management of dyslipidaemia among patients with cardiovascular risk: updated recommendations on identification and follow-up. Eur J Gen Pract. 2005;2: 68-75.
26. Ross R. AtherosclerosisVan inflammatory disease. N Engl J Med. 1999;340: 115-126.
27. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 2002;8: 1211-1217.
28. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86: 515-581.
29. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000; 247: 349-358.
30. Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther. 2009;23: 31-40.
31. Kharbanda R, MacAllister RJ. The atherosclerosis time-line and the role of the endothelium. Curr Med Chem. 2005;5: 47-52.
32. Andersson S, Davis DL, Dahlback H, et al. Cloning, structure and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J Biol Chem. 1989; 264: 8222-8229.
33. Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase. J Biol Chem. 1991;266: 7774-7778.
34. Reiss AB, Martin KO, Javitt NB, et al. Sterol 27-hydroxylase: high levels of activity in vascular endothelium. J Lipid Res. 1994;35: 1026-1030.
35. Bjorkhem I, Andersson O, Diczfalusy U, et al. Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci U S A. 1994;91: 8592-8596.
36. Bjorkhem I, Eggertsen G. Genes involved in initial steps of bile acid synthesis. Curr Opin Lipidol. 2001;12: 97-103.
37. Olkkonen VM, Lehto M. Oxysterols and oxysterol binding proteins: role in lipid metabolism and atherosclerosis. Ann Med. 2004;36: 562-572.
38. Wang X, Rader DJ. Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol. 2007;22: 368-372.
39. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2001;21: 13-27.
40. Meaney S, Bodin K, Diczfalusy U, et al. On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation: critical importance of the position of the oxygen function. J Lipid Res. 2002;43: 2130-2135.
41. Babiker A, Diczfalusy U. Transport of side-chain oxidized oxysterols in the human circulation. Biochim Biophys Acta. 1998;1392: 333-339.
42. Björkhem I, Diczfalusy U. Oxysterols. Friends, foes or just fellow passengers? Arterioscler Thromb Vasc Biol. 2002;22: 734-742.
43. Lange Y, Ory DS, Ye J, et al. Effectors of rapid homeostatic responses of endoplasmic reticulum cholesterol and 3-hydroxy-3-methylglutaryl- CoA reductase. J Biol Chem. 2008;283: 1445-1455.
44. Bellosta S, Corsini A, Bernini F, et al. 27-Hydroxycholesterol modulation of low density lipoprotein metabolism in cultured human hepatic and extrahepatic cells. FEBS Lett. 1993;332: 115-118.
45. Corsini A, Verri D, Raiteri M, et al. Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. Arterioscler Thromb Vasc Biol. 1995;15: 420-428.
46. Bjorkhem I, Skrede S. Familial diseases with storage of sterols other than cholesterol: cerebrotendinous xanthomatosis and phytosterolemia. In: Scriver CR, Beaudet AL, Sly WS, eds. The Metabolic Basis of Inherited Disease. 6th ed. New York, NY: McGraw-Hill; 1989: 1283-1302.
47. Lu R, Arakawa R, Ito-Osumi C, et al. ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler Thromb Vasc Biol. 2008;28: 1820-1824.
48. Fu X, Menke JG, Chen Y, et al. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001;276: 38378-38387.
49. Costet P, Luo Y, Wang N, et al. Sterol-dependent trans-activation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem. 2000;275: 28240-28245.
50. Edwards PA, Kennedy MA, Mak PA. LXRs; oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vascul Pharmacol. 2002;38: 249-256.
51. Iatan I, Alrasadi K, Ruel I, et al. Effect of ABCA1 mutations on risk for myocardial infarction. Curr Atheroscler Rep. 2008;10: 413-426.
52. Reiss AB, Glass AD. Atherosclerosis: immune and inflammatory aspects. J. Invest Med. 2006;54: 123-131.
53. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag. 2008;4: 605-614.
54. Sitia S, Atzeni F, Sarzi-Puttini P, et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev. 2008;8: 281-286.
55. Hayden JM, Brachova L, Higgins K, et al. Induction of monocyte differentiation and foam cell formation in vitro by 7-ketocholesterol. J Lipid Res. 2002;43: 26-35.
56. Fach EM, Garulacan LA, Gao J, et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics. 2004;3: 1200-1210.
57. Reiss AB, Wan DW, Anwar K, et al. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med (Maywood). January 9, 2009; [Epub ahead of print].
58. Zinger H, Sherer Y, Schoenfeld Y. Atherosclerosis in autoimmune rheumatic diseases-mechanisms and clinical findings. Clin Rev Allergy Immunol. November 8, 2008; [Epub ahead of print].
59. Reiss AB, Awadallah NW, Malhotra S, et al. Immune complexes and interferon-F decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res. 2001;42: 1913-1922.
60. Panousis CG, Zuckerman SH. Interferon-gamma induces down regulation of Tangier disease gene (ATP-binding cassette transporter 1) in macrophage-derived foam cells. Arterioscler Thromb Vasc Biol. 2000;20: 1565-1571.
61. Frampton JE, Keating GM. Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs. 2007;67: 2433-2472.
62. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352: 1092-1102.
63. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332: 1302-1308.
64. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155: 1281-1291
65. Baker CS, Hall RJ, Evans TJ, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol. 1999;19: 646-655.
66. Choi HC, Kim HS, Lee KY, et al. NS-398, a selective COX-2 inhibitor, inhibits proliferation of IL-1beta-stimulated vascular smooth muscle cells by induction of HO-1. Biochem Biophys Res Commun. 2008;376: 753-757.
67. Chan ESL, Zhang H, Fernandez P, et al. Effect of cyclooxygenase inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther. 2007;9: R4.
68. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352: 1071-1080.
69. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296: 1633-1644.
70. Mason RP, Walter MF, Day CA, et al. A biological rationale for the cardiotoxic effects of rofecoxib: comparative analysis with other COX-2 selective agents and NSAIDs. Subcell Biochem. 2007;42: 175-190.
71. Mason RP, Walter MF, McNulty HP, et al. Rofecoxib increases susceptibility of human LDL and membrane lipids to oxidative damage: a mechanism of cardiotoxicity. J Cardiovasc Pharmacol. 2006;47(suppl 1): S7-S14.
72. Khanapure SP, Garvey DS, Janero DR, et al. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem. 2007;7: 311Y340.
73. Herlong JL, Scott TR. Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett. 2006;102: 121-131.
74. van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther. 2006;8: R151.
75. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002; 359: 1173-1177.
76. Morabito L, Montesinos MC, Schreibman D, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998;101: 295-300.
77. Wessels JA, Kooloos WM, de Jonge R, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006;54: 2830-2839.
78. 2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. J Leukoc Biol. 2004;76: 727-734.
79. Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in THP-1 human monocytes/macrophages. Arthritis Rheum. 2008;58: 3675-3683.
80. Setakis E, Leufkens HG, van Staa TP. Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib. Arthritis Rheum. 2008;59: 1105-1111.